Citadel Advisors’s VanEck Vectors Generic Drugs ETF GNRX Stock Holding History

Citadel Advisors’s Portfolio GNRX Stock Details GNRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-10,661	Closed	-$259K	–	9231
2017 Q4	$259K	Buy	+10,661	New	+$248K	﹤0.01%	6692
2017 Q3	–	Sell	-15,717	Closed	-$354K	–	8526
2017 Q2	$354K	Sell	15,717 -8,970	-36%	-$202K	﹤0.01%	5637
2017 Q1	$558K	Buy	+24,687	New	+$548K	﹤0.01%	4830

Other funds holding GNRX

APA

American Portfolios Advisors Holbrook, New York $2.36B AUM 14.59% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Citadel Advisors's GNRX Position: Q1 2018 in Review

Citadel Advisors sold out of VanEck Vectors Generic Drugs ETF (GNRX) in Q1 2018, closing a stake of 10,661 shares — an estimated $259K sold.

Citadel Advisors first reported a position in GNRX in Q1 2017 and held it in 3 quarters. The position peaked at $558K in Q1 2017. 2 funds tracked by Wall St. Rank hold GNRX as of Q1 2018.

Citadel Advisors reported no remaining VanEck Vectors Generic Drugs ETF position as of Q1 2018 after selling out during the quarter.
Citadel Advisors sold 10,661 VanEck Vectors Generic Drugs ETF shares in Q1 2018, an estimated $259K.
Citadel Advisors first reported a position in VanEck Vectors Generic Drugs ETF in Q1 2017 and held it in 3 quarters.
Citadel Advisors's VanEck Vectors Generic Drugs ETF position peaked at $558K in Q1 2017.
2 funds tracked by Wall St. Rank held VanEck Vectors Generic Drugs ETF as of Q1 2018.

Based on Citadel Advisors's 13F filing for Q1 2018, filed 11 May 2018.